GN-CORPORATION
26.10.2020 07:05:07 CET | Business Wire | Press release
Caucasian, Hispanic and Afro-American population, when Covid-19 infected, are prone to abnormal blood clotting, that may lead to stroke. Pregnant women and people with comorbidities are also at high risk. Higher mortality has been reported in patients, whose fasting plasma glucose is very high at the time of hospital admission with SARS-COV-2. During this unprecedented pandemic, a prophylaxis to Covid-19 in diabetic population , and strategies for Prevention of Covid-19 associated coagulopathy by consumption of Beta glucan food supplement produced by Black yeast Aureobasidium Pullulans AFO-202 strain has been published in Journal of Diabetes and Metabolic Disorders (https://doi.org/10.1007/s40200-020-00664-4 ) and Thrombosis Journal (https://doi.org/10.1186/s12959-020-00239-6 ) respectively, recommending clinical studies for its validation in Covid-19 patients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201025005031/en/
COVID-19 virus damages blood vessels, causing clot or thrombus formation resulting in stroke and disruption of the body’s blood clotting system, leading to organ damage and death. Metabolic and immune dysregulation leads to higher mortality in diabetes patients. The AFO-202 derived Nichi-Glucan has potentials to alleviate the cytokine storm, minimize coagulation disruption, and prevent complications of Covid-19 by balancing blood glucose & cholesterol, according to the authors, who have earlier published its immune enhancement and modulation capabilities to help tackle Covid-19 (https://doi.org/10.3389/fimmu.2020.01548 ). Pilot studies in Diabetic and Dyslipidemic individuals from south Asian population also have been reported (https://doi.org/10.1155/2012/895370 ).
Unique advantages: Research of Prof. Noboru Fujii on poly-thermo tolerant fungi lead to the successful culture of Aureobasidium Pullulans and Mr. Takashi Onaka (President, Sophy Inc) accomplished its industrial scale GMP production in Kochi, Japan, which was approved by Japanese health ministry as a food additive and in the market since 1996. Among several ß-Glucans produced by extraction and purification methods from sources like yeast-cell wall, Shiitake mushroom, Oats, Algae etc, Nichi Glucan is unique, being secreted as an exo-polysaccharide by AFO-202, possessing a distinct structure, water solubility, high purity, functionality and molecular weight of 30,000. Safety has been confirmed by genotoxicity, repeated and long-term administration tests. Recently, a new strain, N-163 secreted product, having advantageous characteristics to contribute to human health is undergoing studies. Nichi Glucan is available in Japan (www.nichiglucan.com ) and in India (https://www.amazon.in/dp/B08DFDX2HQ ), exported worldwide by GN Corporation.
Disclaimer: Nichi-Glucan is a food supplement, free from 25 most common allergens. It’s not a drug or curative/therapeutic agent.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201025005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Special Olympics Airlift Takes Flight Nationwide; Dove 1 Arrives at St. Paul Downtown Airport19.6.2026 17:09:00 CEST | Press release
Approximately 130 Cessna, Beechcraft and Hawker aircraft and volunteer pilots mobilize to transport more than 800 Special Olympics athletes and coaches to the 2026 Special Olympics USA Games The 2026 Special Olympics Airlift officially took flight today as all participating Cessna, Beechcraft and Hawker aircraft, known as Doves, departed from airports across the country. Dove 1 for arrival day, a Cessna Citation Latitude generously operated by Prent Corporation, landed at St. Paul Downtown Airport (STP) carrying Special Olympic athletes and delegation members, signaling the start of Airlift arrivals for the Special Olympics USA Games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619085293/en/ Special Olympics Airlift takes flight nationwide; Dove 1 arrives at St. Paul Downtown Airport (Photo credit: Textron Aviation). The arrival signals the start of the world’s largest cumulative peacetime airlift spanning more than 40
Record Currency Management Participates in Innovative European Bank for Reconstruction and Development (EBRD) -Backed Mongolian Tugrik Transaction19.6.2026 16:53:00 CEST | Press release
Record Currency Management Ltd (RCM), subsidiary of London-listed Record plc (Record Financial Group), is pleased to announce its participation in an innovative local currency bond transaction issued by the European Bank for Reconstruction and Development (EBRD), supporting the development of Mongolia's capital markets while providing institutional investors with access to attractive frontier market opportunities. RCM is the UK currency management arm of Record Financial Group, the London-listed specialist investment group managing USD 115 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom the Group has built long-standing relationships through its focus on bespoke investment and risk management solutions. Headquartered in London, Record has offices in Hamburg, Zurich, Zug, New York, and Hong Kong. The investment forms part of Record Financial Group's broad
Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 14:29:00 CEST | Press release
Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom